POLYMYOSITIS
Clinical trials for POLYMYOSITIS explained in plain language.
Never miss a new study
Get alerted when new POLYMYOSITIS trials appear
Sign up with your email to follow new studies for POLYMYOSITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug shows promise for Long-Term control of rare muscle disease
Disease control ENROLLING_BY_INVITATIONThis study tests the long-term safety of a drug called efgartigimod PH20 SC in adults with active idiopathic inflammatory myopathy, a group of rare muscle diseases. Participants who completed a previous trial will receive the drug as a shot under the skin for up to 51 months. The…
Matched conditions: POLYMYOSITIS
Phase: PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New hope for myositis: early IVIg may boost recovery
Disease control OngoingThis study tests whether adding intravenous immunoglobulin (IVIg) to standard steroid treatment early in myositis helps patients improve faster. Myositis is a group of rare diseases causing muscle inflammation and weakness. The trial includes 44 adults diagnosed within the past y…
Matched conditions: POLYMYOSITIS
Phase: PHASE2, PHASE3 • Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Immune system overhaul: could CAR T-Cells tame autoimmune disease?
Disease control OngoingThis early-stage trial is testing a new treatment called KYV-101 for people with severe autoimmune diseases like lupus, scleroderma, and vasculitis. The treatment involves taking a patient's own immune cells, modifying them to target and destroy faulty B cells, and giving them ba…
Matched conditions: POLYMYOSITIS
Phase: PHASE1 • Sponsor: David Porter • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC